Cover Image
市場調查報告書

Repaglinide的中國市場

Investigation Report on China Repaglinide Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 334097
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Repaglinide的中國市場 Investigation Report on China Repaglinide Market, 2010-2019
出版日期: 2015年07月02日 內容資訊: 英文 30 Pages
簡介

中國,大概9000萬人的糖尿病患者存在著,那個95%第二型糖尿病感到痛苦。還有趨勢的潛在的患者數一般認為上到2億人。中國的Repaglinide銷售額從2005年到2014年以22%的年複合成長率擴大,到2014年達成了1億2500萬人民幣的規模。

本報告提供中國的Repaglinide市場相關調查,提供您Repaglinide的功用·效果,中國市場上的專利及核准狀況,銷售額·銷售量的變化與預測,價格趨勢,並彙整主要製造商與市場佔有率,競爭環境及其展望,主要製造商簡介等資料。

第1章 Repaglinide的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Repaglinide的市場簡介

  • 專利情形
  • 主要製藥公司
  • 市場規模

第3章 中國的Repaglinide銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的Repaglinide的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國的Repaglinide劑型的相關調查

  • 各劑型的市場佔有率:以銷售額為準
  • 各劑型的市場佔有率:以銷售量為準

第6章 中國的醫院的Repaglinide的標準價格

  • Novo Nordisk A/S (Denmark)
  • Hanson Pharmaceutical
  • Tianjin Kangrui Pharmaceutical Co., Ltd
  • Beijing Wansheng Pharmaceutical Co., Ltd

第7章 中國市場中Repaglinide的主要製藥公司

  • Novo Nordisk A/S (Denmark)
  • Hanson Pharmaceutical
  • Tianjin Kangrui Pharmaceutical Co., Ltd
  • Beijing Wansheng Pharmaceutical Co., Ltd

第8章 中國的Repaglinide的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1507258

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.

Entering China after 2000, insulin secretagogues agent is mainly used for the treatment of type 2 diabetes. Currently, there are only 3 kinds available in the Chinese market, namely, nateglinide, repaglinide and mitiglinide. They share the same mechanism of action, that is to say, they lower blood glucose by stimulating the release of insulin from the beta cells. Compared with sulfonylurea, insulin secretagogues agent reports shorter duration of glucose-lowering action and lower rate of hypoglycemia.

As an insulin secretagogues agent structured different from sulfonylurea, repaglinide is used to control postprandial hyperglycemia. Developed by Novo Nordisk A/S and Boehringer-Ingelheim together, it entered the United States in Apr. 1998.

As the first new prandial glucose regulator, repaglinide belongs to the class of benzoic acid derivative. Containing a chiral carbon atom, it has stereoselective activity and can be absorbed well on an empty stomach or not. As repaglinide is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through kidney, it is more suitable for patients with kidney disorders. Hence its advantage in the clinic. In 2000, repaglinide of Novo Nordisk A/S came to be sold in China under the name of Novonorm. According to CRI's market survey, it has few rivals and takes up a market share of about 89% for sales value while its main competitor Hanson Pharmaceutical only occupies less than 11% of the market. The sales value of repaglinide in sample hospitals was about CNY 125 million in 2014 and CAGR during the period of 2005-2014 reached about 22%.

The market size of repaglinide is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:

  • market size of repaglinide in China
  • major manufacturers of repaglinide for Chinese market and their market share
  • retail price of repaglinide in Chinese market
  • market outlook of repaglinide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Repaglinide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Repaglinide in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Repaglinide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Repaglinide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Repaglinide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Repaglinide in Chinese Hospitals in 2014

  • 6.1. Novo Nordisk A/S (Denmark)
  • 6.2. Hanson Pharmaceutical
  • 6.3. Tianjin Kangrui Pharmaceutical Co., Ltd
  • 6.4. Beijing Wansheng Pharmaceutical Co., Ltd

7. Major Manufacturers of Repaglinide in Chinese Market, 2010-2014

  • 7.1. Novo Nordisk A/S (Denmark)
  • 7.2. Hanson Pharmaceutical
  • 7.3. Tianjin Kangrui Pharmaceutical Co., Ltd
  • 7.4. Beijing Wansheng Pharmaceutical Co., Ltd

8. Market Outlook of Repaglinide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Chart of Selected Charts

  • Chart Patent Registration Information of Repaglinide in China
  • Chart Approval Status of Repaglinide in China
  • Chart Sales Status of Repaglinide in China, 2010-2014
  • Chart Sales Value of Repaglinide in China, 2010-2014
  • Chart Sales Value of Repaglinide by Regions in China, 2010-2014
  • Chart Sales Value of Repaglinide Tablets in China, 2010-2014
  • Chart Sales Value of Repaglinide Capsules in China, 2010-2014
  • Chart Market Share of Major Manufacturers of Repaglinide for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Repaglinide Made by Novo Nordisk A/S, 2010-2014
  • Chart Sales Value and Market Share of Repaglinide Made by Hanson Pharmaceutical, 2010-2014
  • Chart Sales Value and Market Share of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd, 2010-2014
  • Chart Price of Repaglinide Made by Novo Nordisk A/S in Some Chinese Cities in 2014
  • Chart Price of Repaglinide Made by Hanson Pharmaceutical in Some Chinese Cities in 2014
  • Chart Price of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top